DECIDE
Decision-making within cells and differentiation entity therapies
| Coordinatore | THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 3˙313˙022 € |
| EC contributo | 3˙313˙022 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-03-01 - 2017-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
UK (BIRMINGHAM) | coordinator | 753˙274.50 |
| 2 |
NATIONAL UNIVERSITY OF IRELAND, GALWAY
Organization address
address: University Road - contact info |
IE (GALWAY) | participant | 550˙419.30 |
| 3 |
UNIVERSITAET BASEL
Organization address
address: Petersplatz 1 contact info |
CH (BASEL) | participant | 496˙573.88 |
| 4 |
INSTYTUT FARMACEUTYCZNY
Organization address
address: "UL. RYDYGIERA 8, LOK. 17" contact info |
PL (WARSAW) | participant | 448˙620.90 |
| 5 |
CELENTYX LIMITED
Organization address
address: VINCENT DRIVE 97 contact info |
UK (BIRMINGHAM) | participant | 285˙056.62 |
| 6 |
INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL
Organization address
address: Old Brompton Road 123 contact info |
UK (LONDON) | participant | 285˙056.62 |
| 7 |
UNIWERSYTET WROCLAWSKI
Organization address
address: Plac Uniwersytecki 1 contact info |
PL (WROCLAW) | participant | 249˙205.66 |
| 8 |
ORBSEN THERAPEUTICS LIMITED
Organization address
address: ORBSEN BUILDING NATIONAL UNIVERSITY OF IRELAND contact info |
IE (GALWAY) | participant | 244˙814.45 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiation therapy. This type of therapy aims, using only mildly toxic treatments, to induce terminal maturation of leukaemia cells and accelerate their death. WP2 responds to the urgent need to devise milder treatments, especially for older and frailer AML patients. Participants have already identified a number of promising new therapeutic agents. Working across these two complementary areas will train our Early Stage Researchers (ESR) to understand the translation of new fundamental science into the development of new therapies. The ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy, so will provide an excellent scientific training in these areas. Secondments/visits by ESRs to participants who run centres of expertise in leading edge technologies will provide training in these; and the time spent with private sector participants, and the courses they provide, will ensure that ESRs acquire the transferable skills they will need if they are to work well in, and build bridges between, commercial and publicly funded research organisations. ESRs will also receive management training. This research and training, which will develop our ESRs as versatile scientists, will involve the combined efforts of prestigious research institutes and universities, Poland’s leading governmental pharmaceutical R & D institute, two successful biopharmaceutical companies and a leading management consultancy.'